干扰素α对人骨肉瘤U2OS细胞化疗敏感性的影响

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (874 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解干扰素α（IFN-α）对骨肉瘤U2OS细胞化疗敏感性的影响。方法细胞分为对照组、IFN-α组、顺铂组和IFN-α+顺铂组，处理72 h，应用台盼蓝拒染法检测细胞生长抑制率，通过Hochest 33258荧光染色和DNA梯形条带检测凋亡，Caspase-3、8、9的表达由Western blot检测，细胞经Z-VAD-FMK预处理后，再使用顺铂单独或联合IFN-α处理，台盼蓝拒染法检测细胞生长抑制率。结果 IFN-α组、顺铂组、IFN-α+顺铂组细胞生长抑制率均高于对照组，IFN-α+顺铂组细胞生长抑制率高于顺铂组（P < 0.01）。IFN-α+顺铂组出现DNA梯形条带。与顺铂组比较，IFN-α+顺铂组Caspase-3、8、9活性片段的表达增加，差异有统计学意义（P < 0.01）。IFN-α+顺铂+Z-VAD-FMK组细胞生长抑制率低于IFN-α+顺铂组（P ＜ 0.01）。结论 IFN-α通过Caspase依赖性凋亡增强U2OS细胞对顺铂的化疗敏感性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄秀芳1 原向伟2▲ 秦英2 陈忠羡2

关键词 ：干扰素&alpha, 顺铂, 骨肉瘤, 化疗敏感性, 凋亡

Abstract：Objective To study the effect of interferon-α (IFN-α) on chemosensitivity in osteosarcoma U2OS cells. Methods Cells were divided into control group, IFN-α group, Cisplatin group and IFN-α+Cisplatin group. After treatment for 72 hours, cell growth inhibition rate was determined by Trypan Blue exclude test. Apoptosis was evaluated with Hoechst 33258 staining and DNA ladder. Expressions of caspase-3, 8 and 9 were detected through Western blot. After pre-treatment with Z-VAD-FMK, cell was treated with Cisplatin or combination. Growth inhibition was determined with Trypan Blue exclude test. Results Cells growth inhibition rates in IFN-α group, Cisplatin group and IFN-α+Cisplatin group were higher than those in control group, cells growth inhibition rate in IFN-α+Cisplatin group was higher than that in Cisplatin group (P < 0.01). DNA ladder appeared in IFN-α+Cisplatin group. Compared with Cisplatin group, the expression of caspase-3, 8 and 9 in IFN-α+Cisplatin group was significantly increased (P < 0.01). Cells growth inhibition rate of IFN-α+Cisplatin+Z-VAD-FMK group was lower than that of IFN-α+Cisplatin group (P < 0.01). Conclusion IFN-α enhances chemosensitivity to Cisplatin in U2OS cells through caspase-dependent apoptosis.

Key words： Interferon-α Cisplatin Osteosarcoma Chemosensitivity Apoptosis

基金资助:广东省自然科学基金项目（2015A030313835）；
广东省医学科研基金项目（A2013756、A2014781）；
广东省江门市科技计划项目（江科〔2015〕73号-76）。

通讯作者: ▲通讯作者

引用本文:

黄秀芳1 原向伟2▲ 秦英2 陈忠羡2. 干扰素α对人骨肉瘤U2OS细胞化疗敏感性的影响[J]. 中国医药导报, 2021, 18(6): 23-26.
HUANG Xiufang1 YUAN Xiangwei2▲ QIN Ying2 CHEN Zhongxian2. Effect of interferon-α on chemosensitivity in osteosarcoma U2OS cells. 中国医药导报, 2021, 18(6): 23-26.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2021/V18/I6/23

[1] Carina V，Costa V，Sartori M，et al. Adjuvant biophysical therapies in osteosarcoma [J]. Cancers（Basel），2019，11（3）：348-353. doi：10.3390/cancers11030348.
[2] Botter SM，Neri D，Fuchs B. Recent advances in osteosarcoma [J]. Curr Opin Pharmacol，2014，16（1）：15-23. doi：10.1016/j.coph.2014.02.002.
[3] Zhang Y，Yang J，Zhao N，et al. Progress in the chemotherapeutic treatment of osteosarcoma [J]. Oncol Lett，2018，16（5）：6228-6237.doi：10.3892/ol.2018.9434.
[4] Zhang B，Zhang Y，Li R，et al. The efficacy and safety comparison of first-line chemotherapeutic agents （high-dose methotrexate，doxorubicin，cisplatin，and ifosfamide） for osteosarcoma：a network meta-analysis [J]. J Orthop Surg Res，2020，15（1）：51-58. doi：10.1186/s13018-020-1576-0.
[5] Manara MC，Serra M，Benini S，et al. Effectiveness of type Ⅰ interferons in the treatment of multidrug resistant osteosarcoma cells [J]. Int J Oncol，2004，24（2）：365-372.
[6] Lee M，Rhee I. Cytokine signaling in tumor progression [J]. Immune Netw，2017，17（2）：214-227. doi：10.4110/in.2017. 17.4.214.
[7] Gavrieli Y，Sherman Y，Ben-Sasson SA，et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation [J]. J Cell Biol，1992，119（3）：493-501. doi：10.1083/jcb.119.3.493.
[8] Ivashkiv LB，Donlin LT. Regulation of type Ⅰ interferon responses [J]. Nat Rev Immunol，2014，14（1）：36-49. doi：10.1038/nri3581.
[9] Stanifer ML，Pervolaraki K，Boulant S. Differential regulation of type Ⅰ and type Ⅲ interferon signaling [J]. Int J Mol Sci，2019，20（6）：1445-1450. doi：10.3390/ijms20061445.
[10] Morris R，Kershaw NJ，Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway [J]. Protein Sci，2018，27（12）：1984-2009. doi：10.1002/pro.3519.
[11] Gao Z，Zhu M，Wu Y，et al. Interferon-λ induces G1 phase cell cycle arrest and apoptosis in gastric carcinoma cells in vitro [J]. Oncol Rep，2014，32（1）：199-204. doi：10.3892/or.2014.3185.
[12] Post AEM，Smid M，Nagelkerke A. Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer [J]. Clin Cancer Res，2018，24（14）：3397-3408. doi：10.1158/1078-0432.CCR-17-2551.
[13] Kanai T，Suzuki H，Yoshid H，et al. Significance of quantitative interferon-gamma levels in non-small-cell lung cancer patients’ response to immune checkpoint inhibitors [J]. Anticancer Res，2020，40（5）：2787-2793. doi：10.21873/anticanres.14251.
[14] Eit RE，Itani AR，Nassar F，et al. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors [J]. Cancer，2019，125（16）：2818-2828. doi：10.1002/cncr.32130.
[15] Mattila K，Raanta P，Lahtela V，et al. Long-term survival of stage Ⅳ melanoma patients treated with BOLD combination chemotherapy and intermediate-dose subcutaneous interferon-alpha [J]. Anticancer Res，2018，38（11）：6393-6397. doi：10.21873/anticanres.12999.
[16] Makowska A，Wahab L，Braunschweig T，et al. Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway [J]. Oncotarget，2018，9（18）：14228-14250. doi：10.18632/oncotarget.24479.
[17] Tian Y，Wang ML，Zhao J. Crosstalk between autophagy and type Ⅰ interferon responses in innate antiviral immunity [J]. Viruses，2019，11（2）：130-138. doi：10.3390/v11020132.
[18] Provance OK，Lewis-Wambi J. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer [J]. Breast Cancer Res，2019，21（1）：59-66. doi：10.1186/s13058-019-1140-1.
[19] Sandoval R，Xue J，Pilkinton M，et al. Different requirements for the cytostatic and apoptotic effects of type Ⅰ interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines [J]. J Biol Chem，2004， 279（31）：32275-32280. doi：10.1074/jbc.M313830200.
[20] Park YB，Park MJ，Kimura K，et al. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines [J]. Cancer Genet Cytogenet，2002，133（2）：105-111. doi：10.1016/s0165-4608（01）00575-1.
[21] Chen X，Wang KW，Chen YQ. Cisplatin induces apoptosis of A549 cells by downregulating peroxidase V [J]. Eur Rev Med Pharmacol Sci，2018，22（21）：7289-7295. doi：10.26355/eurrev_201811_16265.
[22] Larsen BD，S?覬rensen CS. The caspase-activated DNase：apoptosis and beyond [J]. FEBS J，2017，284（8）：1160-1170. doi：10.1111/febs.13970.
[23] Fritsch M，Günther SD，Schwarzer R，et al. Caspase-8 is the molecular switch for apoptosis，necroptosis and pyroptosis [J]. Nature，2019，575（7784）：683-687. doi：10.1038/s41586-019-1770-6.
[24] Wang Y，Xia C，Lun Z，et al. Crosstalk between p38 MAPK and caspase-9 regulates mitochondria-mediated apoptosis induced by tetra-α-（4-carboxyphenoxy） phthalocyanine zinc photodynamic therapy in LoVo cells [J]. Oncol Rep，2018，39（1）：61-70. doi：10.3892/or.2017.6071.
[25] Li YJ，Zhang GP，Zhao F，et al. Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-κB signaling pathway [J]. Exp Ther Med，2018，15（3）：2365-2373. doi：10.3892/etm.2017.5679.